Moderna Receives Refusal-to-File Letter from the U.S. Food and Drug Administration for Its Investigational Seasonal Influenza Vaccine, mRNA-1010

Refusal to review the submission is inconsistent with feedback at pre-Phase 3 and pre-submission consultations; Moderna

Moderna CEO hails breakthrough mRNA cancer vaccine that halves melanoma recurrence risk with Keytruda

Breakthrough personalized mRNA vaccine cuts melanoma recurrence risk by 50% when combined with Keytruda, Moderna CEO reveals promising five-year results.

Moderna Patent Ruling And New Development Chief Reframe mRNA Growth Story

Moderna (NasdaqGS:MRNA) is involved in an ongoing patent infringement case related to its COVID-19 vaccine, with a recent court ruling addressing claims from Arbutus Biopharma and Genevant. The company has appointed Dr.

Moderna to Enter into Long-Term Strategic Agreement with the Government of Mexico

Signed Memorandum of Understanding supports "Plan Mexico," Mexico's strategic initiative to build a local mRNA

Should You Buy Moderna Before Feb. 13?

Moderna (NASDAQ: MRNA) has been on fire this year, with the biotech's shares up by 39% through Feb. 6. This isn't due to the company's financial results. Moderna has yet to release its fourth-quarter 2025 update. That's coming up on Feb. 13.

Jim Cramer on Moderna: "One of the hottest stocks in the market this year"

Moderna, Inc. (NASDAQ:MRNA) is one of the stocks in focus on Jim Cramer’s game plan. Cramer finished his game plan with the stock, as he commented: Finally, Friday, we’re going to hear from Moderna, one of the hottest stocks in the market this year,